[ABAAcademies] Bergen N, Jaddoe V, Timmermans S, et al
78 Polyethylene glycol liraglutide Polyethylene glycol liraglutide (PEG-loxenatide) is a long-acting GLP-1RA
By virtue of inducing broad cell growth, growth hormone related peptides (CJC-1295, Ipamorelin, and Tesamorelin), carry the potential risk of cancer
Stopped because of side effects: 20% on Survodutide vs 3% on placebo
This is why the over promotion of MHT and GLP-1s, as if they are something every woman should take, is indirectly beneficial to companies like MIDI, because the more people want MHT and GLP-1, the more opportunities to get subscribers for supplements, compounded hormones, and compounded GLP-1s
Additional risks include diabetic retinopathy complications (particularly with semaglutide in patients with pre-existing retinopathy), acute kidney injury (especially with volume depletion from gastrointestinal effects), and rare cases of intestinal obstruction or ileus